Randomized,Double-Blind,Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non–Small-Cell Lung Cancer期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Randomized,Double-Blind,Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non–Small-Cell Lung Cancer

Institution:	2. IBIS (Virgen del Rocio Hospital, Seville University & CSIC), Seville, Spain;3. Cancer Care Center of Frederick, Frederick, Maryland;4. Asklepios Klinik Harburg, Hamburg, Germany;6. Royal Victoria Hospital, Division of Medical Oncology, Montreal, Canada;5. Eli Lilly and Company, Indianapolis, Indiana

Abstract:

Keywords:	Cisplatin Gemcitabine hemotherapy Leukotriene receptor agonist Lung cancer LY293111 Peroxisome proliferators Activated receptor γ agonist
本文献已被 ScienceDirect 等数据库收录！